Topic
Who can take GLP-1s, and who should be careful?
GLP-1 use by women, teens, older adults, type 1 diabetes and post-bariatric patients, with sourced guidance.
GLP-1 After Bariatric Surgery: Does It Work for Weight Regain?Yes — the evidence says it can work. In a 68-week randomized trial, semaglutide 2.4 mg once weekly produced −18.0% body weight versus +0.4% on placebo in people with poor results after gastric bypass or sleeve, with no new safety concerns. No GLP-1 is FDA-approved specifically for post-bariatric use.GLP-1 and Men's Health: Testosterone, Erections, Sperm and MusclePost hoc analyses reported in a conference abstract suggest women lose about 40% more weight than men on GLP-1 drugs. A review of five trials found no negative impact on hormones, sexual function or sperm quality, with possible testosterone gains for men whose low T is driven by obesity [1][10].GLP-1 and Menopause: Weight Loss Evidence and Hormone Therapy EffectsGLP-1 drugs still produce strong weight loss after menopause: tirzepatide cut body weight 23% vs 3% placebo in postmenopausal women, and the STEP pool showed a median −16.4% for semaglutide. Hormone therapy is linked to more loss (16% vs 12% at 12 months), but no trial proves it causes the difference.GLP-1 for Teens: Which Drugs Are Approved and What Studies ShowOnly Wegovy injection (ages 12+) and Saxenda (ages 12+ with body weight over 60 kg) carry a teen weight-loss indication. Mounjaro is labeled for ages 10 and older only for type 2 diabetes, not weight loss. Zepbound is adults-only.GLP-1 for Type 1 Diabetes: What the Research Actually ShowsNo GLP-1 drug is FDA-approved for type 1 diabetes. One small randomized trial found 36% of adults on semaglutide hit a combined glucose-and-weight goal versus 0% on placebo, with weight 8.8 kg lower than placebo at 26 weeks.GLP-1 Over 65: What the Labels, Trials and Medicare Rules ShowNo GLP-1 label sets an upper age limit, and pooled trials find efficacy and safety in adults 65 and older broadly comparable to younger adults, though side effects force stopping more often after 65. Medicare's GLP-1 Bridge covers certain drugs for $50 a month from July 1, 2026 through December 31, 2027.Who Should Not Take GLP-1 Drugs: Contraindications and WarningsOnly two things rule out these drugs outright: a personal or family history of medullary thyroid carcinoma or MEN 2, and hypersensitivity to the drug or its ingredients (Wegovy's label says "known" hypersensitivity; the other three say "serious"). Everything else is a warning or "not recommended."